COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network
코로나19와 고혈압 근거와 실천: HOPE Asia Network의 안내
Review
[키워드] acute respiratory distress
acute respiratory distress syndrome
addition
adverse outcome
adverse outcomes
age
angiotensin
Angiotensin receptor blockers
Angiotensin-converting enzyme
angiotensin-converting enzyme 2
angiotensin-converting enzyme 2 receptors
angiotensin-converting enzyme inhibitors
antihypertensive therapy
Asia
best
Biomarker
Biomarkers
blood pressure
can be used
cardiac injury
cells
Complication
coronavirus
coronavirus 2019 disease
Course
COVID-19
creatinine
cytokine
Cytokine storm
D-dimer
develop
Evidence
facilitate
Factor
Health status
heart failure
help
home blood pressure monitoring
hypertension
include
increase
independent
independent of
Infection
inhibitor
Kidney injury
maintain
maintenance
management
MONITOR
myocardial injury
N-terminal
N-terminal pro-B-type natriuretic peptide
network
new infection
Other
outcome
pandemic
Patient
Patient management
patients
patients with COVID-19
peptide
poor prognosis
pro-B-type natriuretic peptide
Psychological well-being
RAS
RAS inhibitor
RAS inhibitors
receptor
regular exercise
Renin
renin-angiotensin system
respiratory distress
Respiratory distress syndrome
resulting
risk
risk factor
Risk factors
risk stratification
SARS-CoV-2 virus
SARS-CoV-2 virus infection
serum creatinine
severe COVID-19
social distancing
syndrome
Telemedicine
the SARS-CoV-2 virus
thrombosis
troponin
virus infection
[DOI] 10.1111/jch.13917 PMC 바로가기 [Article Type] Review
[DOI] 10.1111/jch.13917 PMC 바로가기 [Article Type] Review